

Product Information

Product ID P9200

CAS No. 502632-66-8

Chemical Name (1E,4S,4aR,5R,6aS,9aR)-5-(acetyloxy)-1-[(di-2-propen-1-ylamino)methylene]-4,4a,5,6,6a,8,9,9a-octahydro-11-hydroxy-4-(methoxymethyl)-4a,6a-dimethyl-cyclopenta[5,6]naphtho[1,2-c]pyran-

Synonym Sonolisib

Formula C₂₉H₃₅NO₈

Formula Wt. 525.59

Melting Point 102°C-107°C


Purity ≥98%

Solubility Methanol, DMSO(50mM), Ethyl acetate, Ethanol

Store Temp -20°C

Ship Temp Ambient

Description PX-866 is a wortmannin analog that inhibits PI3K, exhibiting anticancer chemotherapeutic and anti-angiogenic activities. PX-866 is currently in clinical trials as a standalone or combination therapy in the treatment of advanced solid tumors. PX-866 inhibits invasion and angiogenesis and induces autophagy in glioblastoma cells. In animal models of cancer, PX-866 inhibits tumor growth and increases survival time. PX-866 also inhibits motility of cancer cells.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
P9200	1 mg	\$63.30
P9200	5 mg	\$203.90
P9200	10 mg	\$351.10

References Bowles DW, Ma WW, Senzer N, et al. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. *Br J Cancer*. 2013 Sep 3;109(5):1085-92. PMID: 23942080.

Koul D, Shen R, Kim YW, et al. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. *Neuro Oncol*. 2010 Jun;12(6):559-69. PMID: 20156803.

Howes AL, Chiang GG, Lang ES, et al. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. *Mol Cancer Ther*. 2007 Sep;6(9):2505-14. PMID: 17766839.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.